🔎 Trials Near Me

Home › Linfoma di Burkitt › Illinois › Chicago

Studi clinici su Linfoma di Burkitt a Chicago, IL

14 studi su Linfoma di Burkitt cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

In reclutamentoFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
366 Days – 46 Years · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

In reclutamentoFase 3
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Illinois, Chicago
  • e altri 1
Età da 18 a 39 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT03150693

Blinatumomab Consolidation in Real World

In reclutamentoStudio osservazionaleVolontari sani benvenuti
  • Northwestern University, Chicago
  • The University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07117136

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

In reclutamentoFase 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

In reclutamentoFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

In reclutamentoFase 2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Età da 1 a 30 · Tutti i sessi · Aggiornato il 1 set 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

In reclutamentoFase 3
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
365 Days – 25 Years · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

In reclutamentoFase 2
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Età da 7 a 25 · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05082519

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

In reclutamentoFase 1/2
  • Research Site, Chicago
Età 12 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06137118

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

In reclutamentoFase 1/2
  • Research Site, Chicago
Età 12 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT07109219

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

In reclutamentoFase 2
  • University of Chicago Comprehensive Cancer Center, Chicago
Età da 18 a 54 · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06918431

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

In reclutamentoFase 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 nov 2025 · NCT03595917

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

In reclutamentoFase 1/2
  • University of Chicago, Chicago
Età da 15 a 50 · Tutti i sessi · Aggiornato il 9 set 2025 · NCT04150497

Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)

In reclutamento
  • University of Chicago Medicine Comprehensive Cancer Center, Chicago
Età da 18 a 50 · Tutti i sessi · Aggiornato il 19 giu 2025 · NCT06785324

Studi su Linfoma di Burkitt in altre città

Altri studi a Chicago

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.